Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8298093 | 0.82 | CYP2D6 (0.32) | BRD4 | |
| SCHEMBL8298088 | 0.81 | SRD5A1 (0.33) | KMT2A | |
| SCHEMBL26750315 | 0.74 | KMT2A (0.37) | KMT2ATACR1 | |
| SCHEMBL13185492 | 0.73 | — | — | |
| SCHEMBL12567851 | 0.73 | — | — | |
| SCHEMBL9738824 | 0.73 | — | — | |
| SCHEMBL8299329 | 0.72 | SMN1; SMN2 (0.36) | KMT2ABRD4 | |
| SCHEMBL8298074 | 0.71 | KMT2A (0.35) | KMT2A | |
| SCHEMBL5991725 | 0.68 | — | — | |
| SCHEMBL8297562 | 0.68 | BRD4 (0.33) | KMT2ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058292-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767699-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA, L.P. (US) | 2010-08-03 | — | — | US | disclosed |
| WO-2005007641-A1 | 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256111-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | CHRNA10, ACHE, SNCA | KMT2A 771/4885TACR1 51/4885BRD4 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.